Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the ®rst time the in vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein ± protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant DElk-1 and c-Fos protooncogene. Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. Interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-1 that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells. Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway. Furthermore, we have observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the ®rst time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein. All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.
Introduction
BRCA1, a familial breast and ovarian cancer susceptibility gene is mutated in approximately 45% of the families with inherited breast cancers and 80 ± 90% of families with inherited breast and ovarian cancers (Couch and Weber, 1996; Easton et al., 1995; Ford et al., 1995; Miki et al., 1994; Struewing et al., 1997) . Recently, loss of heterozygosity (33%) at the BRCA1 locus and reduced expression of BRCA1 mRNA was also observed in sporadic breast cancers (Katsama et al., 2000; Ozcelik et al., 1998) . The BRCA1 gene spans approximately 100 kb on chromosome 17q21.3, is composed of 22 coding exons and encodes a protein of 1863 amino acids (Miki et al., 1994) . We have recently isolated and characterized two new naturally occurring variants of BRCA1, BRCA1a/p110 and BRCA1b/p100 (Wang et al., 1997) which are abundantly expressed in both non-malignant and tumorderived breast cells (Lu et al., 1996) , Rao et al., unpublished results . Other groups have independently identi®ed these isoforms and have designated BRCA1a as BRCA1-D11b (Wilson et al., 1997) , BRCA1s (Lu et al., 1996) and BRCA1b as BRCA1s-9, 10 (Lu et al., 1996) . Wild-type BRCA1 and splice variants BRCA1a/ 1b proteins bind to a number of cellular proteins. The unique amino-terminal RING ®nger domain interacts with BARD1 (Wu et al., 1996) , BAP1 (Jensen et al., 1998) , BIP (Wang et al., 1997) , E2F transcriptional factors, cyclins and cyclin-dependent kinases (Wang et al., 1997) . Two`BRCT' (BRCA1 carboxyl terminus) repeats present at the carboxy-terminal region of BRCA1 proteins (Bork et al., 1997; Callebaut and Mornon, 1997; Koonin et al., 1996) are involved in transcription activation, growth inhibition and tumor suppression (Chapman and Verma, 1996; Humphrey et al., 1997; Monteiro et al., 1996; Rao et al., 1996; Thompson et al., 1995) . The BRCT domains of BRCA1 are targets for cancer associated mutations (Couch and Weber, 1996) . Recently, we and others have shown the N-and C-terminal regions of BRCA1, BRCA1a and BRCA1b proteins to activate transcription when fused to GAL4 DNA binding domain (Chapman and Verma, 1996; Cui et al., 1998b; Monteiro et al., 1996) and associate with RNA polymerase II holoenzyme (Scully et al., 1997a) and CBP/P-300 co-activator (Cui et al., 1998a) , suggesting a role for BRCT domains in the regulation of transcription. The BRCT domain also binds to RNA helicase A (Anderson et al., 1998) , ctBP interacting protein (Yu et al., 1998) , tumor suppressor p53 protein (Chai et al., 1999; Somasundaram et al., 1997; Zhang et al., 1998) and BRCA2 protein (Chen et al., 1998) . BRCA1 has also been shown to interact with DNA repair protein Rad51 (Scully et al., 1997b) and c-myc oncoprotein . Thus, the association with these proteins mediate the involvement of BRCA1 proteins in growth/tumor suppression (Holt et al., 1996; Humphrey et al., 1997; Rao et al., 1996; Thompson et al., 1995) , induction of apoptosis , cell cycle control, transcriptional transactivation (Chai et al., 1999; Chapman and Verma, 1996; Monteiro et al., 1996; Zhang et al., 1998) , DNA repair and the maintenance of genomic stability (Brugarolas and Jacks, 1997; Lane et al., 1995; Marquis et al., 1995; Scully et al., 1997b) .
The Elk-1 gene is a member of a subfamily of ETS domain proteins called ternary complex factors (TCFs), i.e. Elk-1, SAP-1 and NET/ERP/SAP2/Elk-3 (Dalton and Treisman, 1992; Giovane et al., 1994; Hipskind et al., 1991; Lopez et al., 1994; Nozaki et al., 1996; Price et al., 1995; Rao et al., 1989) that associate with the serum response factor (SRF) to regulate the transcription of c-Fos protooncogene (Dalton and Treisman, 1992; Hipskind et al., 1991) . The Elk-1 gene codes for two splice variants Elk-1 (Rao et al., 1989) and DElk-1 which function as sequence speci®c transcriptional activators Rao and Reddy, 1992) , are substrates for MAP kinases (Hill et al., 1993; Marais et al., 1993; and JNK protein kinases (Gupta et al., 1996; Whitmarsh et al., 1995) , and induce apoptosis (Shao et al., 1998) . Elk-1 is an ecient substrate for all three classes of MAPK, unlike SAP-1 which is activated only by ERK and p38 MAPK, and Net is activated by expression of oncogenic Raf (Wasylyk et al., 1998) . Despite the high degree of sequence similarity within the ETS domain (*80%) both Elk-1 and SAP1 proteins show dierent DNA binding speci®cities . In this study, we have found ternary complex factor Elk-1 to interact with BRCA1 splice variants BRCA1a and BRCA1b proteins. We demonstrate in vitro and in vivo interactions between Elk-1 and BRCA1 proteins by using GST pull-down assays, co-immunoprecipitations/ Western blot analysis and mammalian two-hybrid assays. BRCA1 proteins bind to the ETS DNA-binding domain of Elk-1. Interestingly, although both Elk-1 and SAP-1 bind to BRCA1 proteins, it is only Elk-1 but not SAP-1 that can enhance the growth suppressive function of BRCA1a/1b proteins in breast cancer cells. Furthermore, overexpression of BRCA1a and BRCA1b inhibits MEK-induced c-Fos SRE promoter activation in vivo. These ®ndings suggest that BRCA1 proteins may function as growth/tumor suppressors by regulating the expression of c-Fos.
Results and Discussion

BRCA1 inhibits c-Fos promoter activity in breast cancer cells
One of the speci®c changes brought about by numerous oncogenes is the constitutive elevation of cFos proto-oncogene expression which may represent a causal event in the transformation process. Similarly, the c-Fos basal promoter was shown to be suppressed by wild type p53 tumor suppressor. We therefore determined the activity of the c-Fos SRE (a DNA promoter element whose activity is regulated by a variety of growth promoting events) by using a SRE-TK-CAT reporter in NIH3T3 or MCF-7 cells that have been transfected with either antisense RNA to BRCA1a or BRCA1a . We observed high levels of CAT activity in BRCA1a antisense transfected NIH3T3 cells ( Figure  1a ). Similarly transfection of SRE-TK-CAT reporter plasmid in BRCA1a transfected MCF-7 cells showed *98% reduction in the levels of CAT activity compared to parental pcDNA3 transfected MCF-7 cells, unlike PSV2CAT transfected cells (data not given). These results suggested that this eect may be unique to SRE-dependent reporters (Figure 1b) . In fact, SRE activity is dependent upon the activation by phosphorylation of ternary complex factor Elk-1. The results also suggest that BRCA1 could directly or indirectly regulate the function of Elk-1 target genes like c-Fos, or Elk-1 could be a potential downstream target of BRCA1 proteins in the apoptotic or tumor suppressive pathway. These observations lead us to investigate whether Elk-1 associates with BRCA1 proteins.
BRCA1 interacts with Elk-1 and SAP-1 but not DElk-1 and c-Fos in vitro To investigate whether BRCA1a/1b proteins associate directly with Elk-1, in vitro binding was performed with in vitro translated Elk-1 and GST-BRCA1a or GSTBRCA1b proteins using a GST fusion protein pulldown assay as described previously (Cui et al., 1998a; Wang et al., 1997) . The in vitro translated 35 Smethionine-labeled Elk-1 protein was passed through GST-BRCA1a, GST-BRCA1b, and a GST control column. Elk-1 was found to bind speci®cally to GSTBRCA1a and GST-BRCA1b proteins but not to GST (Figure 2a) . Similarly, we also studied the in vitro binding of another Elk-1 related protein SAP1a, DElk-1 and c-Fos to BRCA1a/1b proteins. In vitro translated full-length SAP1a ( Figure 2b proteins with endogenous Elk-1 protein in vivo, we incubated cell lysates obtained from a human breast cancer cell line CAL-51 with GST-immobilized on GSH beads and BRCA1a fusion protein conjugated GSH beads. The beads were washed and the bound proteins were subjected to Western blot analysis using Elk-1 speci®c polyclonal antibody as described previously (Shao et al., 1998 ). An *62 kD band corresponding to the size of Elk-1 protein was detected in the lysates of GST-BRCA1a beads but not control GST beads (Figure 3b ). These results suggest the association of BRCA1 proteins with endogenous Elk-1.
Localization of the BRCA1 binding domain of Elk-1
To map the region of Elk-1 which binds to BRCA1a/ 1b proteins, a series of carboxy-and amino-terminal Elk-1 deletion mutants expressed and puri®ed as GST fusion proteins (Rao and Reddy, 1992) were incubated with in vitro translated full-length BRCA1b protein and subjected to GST pull-down assay. Our results suggested the binding of BRCA1b protein to the aminoterminal ETS domain (amino acids 1 ± 89) of Elk-1 protein ( Figure 4a ). This winged-helix ± turn-helix (wHTH) ETS domain of Elk-1, which is highly conserved among all ETS proteins, mediates both DNA binding (Rao and Reddy, 1992 ) and protein ± protein interactions with itself (Drewett et al., 2000) or other proteins (Yates et al., 1999) . If this ETS domain is sucient for interaction with BRCA1 proteins, then one should expect all the other Ets related proteins to bind to BRCA1. We, therefore, studied the binding of GST-BRCA1a/1b proteins to in vitro translated fulllength ETS-1, ERG-2, and Fli-1 using a GST pulldown assay. Our results suggest weak binding of ETS-1, ERG-2 and Fli-1 to BRCA1 proteins (Figure 4b , c,d).
BRCA1 Elk-1 interaction in vivo in mammalian cells
To investigate whether Elk-1 and BRCA1 could associate in mammalian cells, we performed a coimmunoprecipitation followed by Western blot analysis in co-transfected COS-7 cells. We co-transfected COS-7 cells with GAL4 Elk-1 (residues 1 ± 205) and FLAGepitope tagged full-length BRCA1a. Forty-eight hours post transfection, cell lysates were prepared and subjected to immunoprecipitation with FLAG antibody. This immuno-precipitated complex was subjected to SDS ± PAGE followed by Western blotting with GAL4 (DBD) antibody. As shown in Figure 5a , Elk-1 was co-precipitated with the full-length FLAG BRCA1a (lane 3) using a FLAG antibody but not using an IgG antibody (lane 1). Taken together these results suggest that Elk-1 and BRCA1 proteins associate in vivo. To further document the in vivo binding of Elk-1 and BRCA1 proteins, we next showed that endogenous Elk-1 associates with endogenous BRCA1 proteins in CAL51 cells. Cell lysates from CAL51 cells were immunoprecipitated with Elk-1 antibody and the immunocomplexes were subjected to a b Figure 1 Functional assay for SRE activity in stable NIH3T3 and NIH3T3 BRCA1 AS cells (a) and in stable MCF-7 pcDNA and MCF-7 BRCA1a transfectants (b). pBLSRE-TK CAT reporter plasmid and pCH110 internal reference plasmids were co-transfected into the indicated cells using the Promega transfection kit as described . The chromatogram represents a typical experiment Western blot analysis using BRCA1 antibodies. As shown in Figure 5b , lane 2, both BRCA1a and BRCA1b proteins were co-precipitated with the Elk-1 antibody but not with a control IgG antibody ( Figure  5b , lane 1). Having established that the ETS domain of Elk-1 can directly associate with full-length BRCA1a and BRCA1b proteins in vitro, we next studied the interaction in vivo using the mammalian two-hybrid system. We have subcloned the full-length BRCA1a and BRCA1b cDNA's in frame with the GAL-4 DNA binding domain vector. The ETS domain of Elk-1 has been cloned in frame with the VP16 activation domain VP16-Elk-1 (1 ± 89). COS-7 cells were co-transfected with VP16-Elk-1 and GAL4 BRCA1a or GAL4 BRCA1b and pG5E1bCAT as a reporter. Figure 5c shows that using the two-hybrid assay, the VP16-Elk-1 S-methionine-labeled full-length Elk-1 (a), or full-length SAP1a (b), or DElk-1 (c), or c-Fos (d), and subjected to GST pull-down assay as described (Chai et al., 1999) . In lane 4 (a), lane 1 (b), lane 1 (c), lane 1 (d) 1/12th of the in vitro translated protein that was used for binding was loaded directly
Elk-1 binds BRCA1 proteins and enhances growth suppression Y Chai et al protein stimulates GAL4 BRCA1a and GAL4 BRCA1b activity consistent with the in vitro binding results ( Figure 3a) . As expected from our previous work (Cui et al., 1998a) , this activation is not seen with the pSGVP16 vector alone or with both full-length GAL4 BRCA1a and GAL BRCA1b (Figure 5c ). These results further con®rm the in vivo interactions of BRCA1 and Elk-1 proteins.
Elk-1 but not DElk-1 and SAP1a enhances the growth suppressive activity of BRCA1a/1b in human breast cancer cells
We and others have shown the BRCA1, BRCA1a and BRCA1b proteins to function as growth/tumor suppressors and induce apoptosis of human breast, ovarian and prostate cancer cells (Fan et al., 1998; Holt et al., 1996; Rao et al., 1996; Shao et al., 1996; Zhang et al., 1998; and Rao, unpublished results) . We therefore studied whether Elk-1 may change BRCA1a/ b mediated growth suppression of human breast cancer cells. We co-transfected BRCA1a or BRCA1b and Elk-1 cDNA's into MCF-7 breast cancer cells and analysed their eect on G418 colony formation. We have used MCF-7 cells lines because this cell line lacks one copy of a 2 Mb region which contains the BRCA1 gene, the growth of these cells is inhibited by the over-expression of BRCA1 (Holt et al., 1996) , BRCA1a/1b proteins ( Figure 6 , Rao, unpublished results), this cell line contains wild type p53 and expresses Elk-1 protein. The expression of BRCA1a alone (pcDNA BRCA1a), BRCA1b alone (pcDNA BRCA1b) or Elk-1 alone (pcDNA Elk-1) resulted in reduction in the number of G418 colonies formed when compared to pcDNA3 vector (Figure 6 ), unlike DElk-1 (pcDNA DElk-1) or SAP1a alone (pcDNA SAP1a). The co-expression of BRCA1a/1b and Elk-1 (Figure 6a ,b) but not DElk-1 (Figure 6a ,b) or SAP1a (Figure 6c ) signi®cantly decreased the number of colonies. These results suggest that Elk-1 augments the growth suppressive function of BRCA1a/1b proteins in human breast cancer cells and demonstrates for the ®rst time that BRCA1a/1b proteins like BRCA1 can function as growth suppressors of human breast cancer cells. Similar enhancement in growth suppression of BRCA1 was previously observed for another protein BAP1 (Jensen et al., 1998) . Alternately, it could be possible that the results that we have obtained using Elk-1 and BRCA1 may represent an additive eect rather than an interactive eect. Future studies should resolve these issues. Thus, the majority of exon 11 sequences that are deleted in BRCA1a/1b isoforms (residues 263 ± 1365) are not necessary for the growth suppression function of BRCA1 proteins. Our results also show that altering Elk-1 activity by elevated levels of expression of Elk-1 in human breast cancer cells can result in growth suppression of human breast cancer cells. These studies also reveal how highly homologous ETS proteins like Elk-1 and SAP1a can exhibit distinct biological properties. Figure 4 BRCA1a/1b proteins bind to the ETS domain of Elk-1, ETS-1, ERG-2 and Fli-1 proteins. (a) GST, GST-Elk-1 (amino acids 1 ± 428), GST Elk-1 (amino acids 1 ± 89) and GST Elk-1 (amino acids 305 ± 428) proteins were expressed, puri®ed on beads and incubated with in vitro translated 35 S-methionone labeled BRCA1b and subjected to GST pull-down assay as described (Wang et al., 1997) . GST, GST-BRCA1a, GST-BRCA1b proteins were puri®ed on beads and incubated with in vitro translated 35 S-methionine labeled ETS-1 (b) or ERG-2 (c) or Fli-1 (d) and subjected to GST pull-down assay as described (Wang et al., 1997) In vivo interaction of Elk-1 with BRCA1 proteins. (a) COS-7 cells were co-transfected with GAL4-Elk-1 and FLAG epitope tagged BRCA1a plasmids. After 48 h of transfection, cell lysates were subjected to immunoprecipitation using an IgG antibody (lane 1) or GAL4 (DBD) antibody (lane 2) or an anti-FLAG antibody (lane 3). The immunocomplex was then separated on an SDS ± PAGE and subjected to Western blot analysis using an anti-GAL4 (DBD) antibody. Elk-1 was co-precipitated with FLAG-BRCA1a by the anti-FLAG antibody. (b) CAL-51 cells were used to study the endogenous interaction between BRCA1a/1b and Elk-1. CAL-51 cell lysates were subjected to imunoprecipitation using an IgG antibody (lane 1) or Elk-1 antibody (lane 2). The immunocomplex was then separated on an 8% SDS ± PAGE and subjected to Western blot analysis using BRCA1 (D-20) antibody. BRCA1a/1b proteins are indicated by arrows. (c) Full-length BRCA1a and BRCA1b interact with the ETS domain of Elk-1 in a mammalian two-hybrid system. COS-7 cells were co-transfected with 6 mg of 17 MzCAT reporter plasmid 1 mg of VP16 expression plasmids and 1 mg of GAL4 expression plasmids as described (Cui et al., 1998a) . The CAT activity shown represents fold activation compared with the VP16 vector alone
BRCA1 inhibits ERK-1 mediated induction of the c-Fos promoter via the SRE
Elk-1 plays a key role in c-Fos induction following stimulation with growth factors and mitogens. Our results suggest that BRCA1 proteins inhibit c-Fos promoter activity in breast cancer cells that have been stably transfected with BRCA1a. We therefore studied the eect of over expression of BRCA1a/1b proteins on the activity of an SRE-driven reporter in NIH3T3 cells. A constitutively active MEK protein was co-transfected to stimulate the c-Fos reporter via the extracellular signal-related kinase (ERK) pathway. Co-transfection of increasing amounts of BRCA1a/1b caused a dose-dependent reduction in the activity of the reporter in response to MEK induction ( Figure 7 ). These results demonstrate that the BRCA1 proteins may function by inhibiting MEK-inducible c-Fos promoter activation. We can speculate that this inhibition can occur either via the Elk-1 SRE-SRF ternary complex on the c-Fos promoter, or via competing for a common factor(s).
Physiological relevance of Elk-1-BRCA1 interaction to c-Fos activity
Full-length Elk-1 binds to BRCA1a/1b proteins in vitro and in vivo and enhances the growth suppression properties of BRCA1a/1b proteins in colony formation assays. These results demonstrate for the ®rst time a key link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 proteins. Indeed, over expression of BRCA1a/1b proteins in human breast cancer cells and NIH3T3 cells causes inhibition of the activity of the c-Fos promoter, indicating that Elk-1 could be a target for BRCA1a/1b mediated inhibition of c-Fos promoter activity. Currently, the mechanism Figure 6 Elk-1 unlike DElk-1 and SAP1a enhances BRCA1a/1b mediated growth suppression of MCF-7 cells. MCF-7 (1610 6 ) were co-transfected with (a) and (b) pcDNA3 or pcDNA3 Elk-1 or pcDNA3 DElk-1 or (c) pcDNA3 SAP1a either alone or in the presence of pcDNA3 BRCA1a or pcDNA3 BRCA1b plasmid constructs as shown. Twenty-one days later, cells were stained with crystal violet and colonies counted. The experiment was repeated four times using dierent preparations of plasmid DNA. Inhibition of colony formation is shown in percentage with the number of neomycin-resistant colony resulting from pcDNA3 transfection set as 100% Figure 7 BRCA1a and BRCA1b proteins inhibit ERK-mediated induction of the c-Fos SRE reporter. NIH3T3 cells were cotransfected with SREx2-luc reporter plasmid, pCMVMEK-1 either in the absence or presence of pcDNA BRCA1a/1b. All values and standard errors were calculated from averages of triplicate samples and are representative of three independent experiments Elk-1 binds BRCA1 proteins and enhances growth suppression Y Chai et al of tumor suppression by BRCA1 is not well understood. Previous studies have suggested that one mechanism by which BRCA1 protein may contribute to cell cycle arrest and growth/tumor suppression is through the induction of p21 WAF1/CIP1 (Chai et al., 1999; Somasundaram et al., 1997) . It may be possible that BRCA1 functions are either regulated or mediated through interactions with cellular proteins like Elk-1, and disruption of this protein ± protein association by germ-line mutations in BRCA1 could be one important step in tumorigenesis. Alternately, wild type BRCA1 could cooperate with Elk-1 in growth inhibition unlike the mutant form. Future work will be directed towards studying whether Elk-1/BRCA1 interaction can be disrupted by BRCA1 mutations that segregate with breast cancer and studying the mechanism of down regulation of c-Fos transcriptional activity mediated by BRCA1. This would provide substantial evidence for the physiological relevance of this interaction in human breast/ovarian and prostate cancers.
Materials and methods
GST pull-down assay
GST-BRCA1a and GST-BRCA1b were expressed and puri®ed from E-coli as reported previously (Wang et al., 1997) . For in vitro binding assay 35 S-methionine labeled in vitro translated full-length Elk-1 (Rao et al., 1989), SAP1a (Dalton and Treisman, 1992) , DElk-1 , c-Fos (Abate et al., 1991) , ETS-1 (Reddy and Rao, 1990) , ERG-2 (Rao et al., 1987) and Fli-1 proteins were diluted in TNN buer (50 mM Tris-Hcl-pH7.4, 150 mM Nacl, 0.5% IGEPAL CA-630) containing 1 mm PMSF, 10 mg/ml leupeptin, 3% aprotinin and 1 mM sodium orthovanadate. The solutions were precleared with GSH beads for 1 h and then incubated with GST or GST-BRCA1a or GST-BRCA1b beads for 2 h at 48C. The beads were then washed six times in TNN buer and heated in SDS sample buer and loaded on a 10% SDS ± PAGE. Similarly, GSTElk-1 (residues 1 ± 428), GST-Elk-1 (residues 1 ± 89) and GST-Elk-1 (residues 305 ± 428) were expressed and puri®ed as described previously (Rao and Reddy, 1992) . For in vitro binding experiments, full-length in vitro translated BRCA1b was tested for binding to the dierent deletion mutants of Elk-1 as described above for GST pull-down assay. The gels were ®xed, treated with enhance, dried and exposed to X-ray ®lms or exposed and scanned using a Fuji BioImaging analyser.
Co-immunoprecipation and Western blot analysis
COS-7 cells were maintained in Dulbecco's Modi®ed Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS). These cells were transfected with GAL4-Elk-1 (residues 1 ± 205) or GAL4-Elk-1 (residues 1 ± 205) and FLAG-BRCA1a to a total of 20 mg DNA using the calcium phosphate mammalian transfection system (Invitrogen). Forty-eight hours after transfection, cells were lysed in lysis buer and the supernatant was subjected to immunoprecipitation with either normal IgG or GAL4 (DBD) antibody or FLAG antibody as described previously (Wang et al., 1997) . SDS ± PAGE and Western blotting using GAL4 (DBD) polyclonal antibody (Santa Cruz Biotechnology) was carried out subsequently as described previously (Cui et al., 1998a) . Similarly, CAL-51 cells were used to study the endogenous interaction of Elk-1 with BRCA1 proteins. CAL-51 cells lysates were immunoprecipitated with either normal IgG or polyclonal anti-Elk-1 antibody (New England Biolabs) and the complexes were run on 8% SDS ± PAGE gel and subjected to Western blot analysis using D-20 polyclonal anti BRCA1 antibody (Santa Cruz Biotechnology).
In vitro co-immunoprecipitation
In vitro translation of full-length Elk-1 (pcDNA-Elk-1) and full-length BRCA1a (pcDNA-BRCA1a) was done with the TNT quick-coupled transcription/translation system (Promega). In vitro co-immunoprecipitation was performed by mixing 40 ml of rabbit reticulocyte lysate containing radiolabelled full-length Elk-1 with 40 ml of reticulocyte lysate containing radiolabeled full-length BRCA1a or with 40 ml of an uncharged reticulocyte lysate. Equal aliquots of samples were diluted in buer and immunoprecipitated at 48C for 2 h with 1 ml of either Elk-1 antibody (#9182, NEB) or BRCA1 polyclonal antibody (SC-641, Santa Cruz) or normal IgG. Protein A Sepharose beads were added and the incubation was continued for 16 h. The beads were then pelleted by brief centrifugation and washed three times in RIPA buer, boiled for 2 min in SDS loading buer and pelleted by centrifugation. The supernatant was then loaded on a SDS 10% polyacrylamide gel.
Cell culture, transfection and reporter gene assays
NIH3T3, NIH3T3-BRCA1
AS cells, MCF-7, MCF-7-pcDNA, MCF-7-BRCA1a #4, MCF-7-BRCA1a #5, and COS-7 cells were maintained in DMEM supplemented with 10% FBS and 200 mg/ml G418 as required. For reporter gene assays, c-Fos SRE-driven reporter (SRE-TK CAT 6 mg) were cotransfected with CH110 (5 mg) using the calcium phosphate method (Promega) as described previously . DNA concentrations were normalized with Gem-3 vector. Similarly NIH3T3 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). Triplicate transfections were carried out in 100 mm petri dishes using SRE62-Luc reporter (5 mg) vector and pCMVMEK-1 either in the absence or presence of 0.5, 1.0, 3.0, 6.0 mg of pcDNA BRCA1a/1b, respectively. Luciferase assays were carried out as described by the manufacturer (Promega). All values and standard errors were calculated from averages of triplicate samples and are representative of three independent experiments. For two-hybrid analysis in mammalian cells, full-length BRCA1a and BRCA1b cDNAs were subcloned in frame with the GAL4 DNA binding domain vector obtained from P Chambon (Cui et al., 1998a) . ETS domain of Elk-1 (residues 1 ± 89) was subcloned in frame with the VP16 transactivation domain vector pSGVP16 . G5E1bCAT reporter plasmid was a gift from T Kouzarides. COS-7 cells were co-transected with pSGVP16 Elk-1 alone (1 mg) or in the presence of GAL4-BRCA1a or GAL4-BRCA1b and G5E1bCAT reporter plasmid (6 mg) as described (Cui et al., 1998a) . After 48 h post transfection, cell extracts were prepared and subjected to b-galactosidase and CAT assays as described (Cui et al., 1998a) . The CAT assays were quantitated with a Fuji PhosphoImager. The experiments were repeated several times.
Colony suppression assay
MCF-7 cells, at 1.5610 5 cells/10 cm dish were transfected with 20 mg of plasmid DNAs (pcDNA3, pcDNA-BRCA1a/ 1b, pcDNA-Elk-1, pcDNADElk-1, pcDNA-SAP1a, etc.) using the calcium phosphate mammalian transfection system from Promega. The next day, cells were washed twice in 16PBS and re-fed with fresh medium (DMEM supplemented with 10% FBS). Twenty-four hours later, the cells were trypsinized and plated into six 10 cm petri dishes containing complete medium and 600 mg/ml G418. Cells were fed with medium containing G418 every 3 ± 4 days. Cells were ®xed approximately 18 ± 21 days after transfection in methanolacetic acid (3 : 1) for 1 h at 7208C and stained for colonies with crystal violet.
Preparation of total cell extract, protein binding and Western blot analysis CAL-51 cells were washed in ice-cold PBS and scraped into 1 ml of TNN buer (Wang et al., 1997) and lysed by rotating for 30 min. The lysates were centrifuged at 14 000 g for 30 min and subjected to GST pull-down assay. For protein binding assay, cell extracts were precleared overnight with GSH beads and then incubated with either GSH protein conjugated GSH beads or GST-BRCA1a. Proteins were incubated with GSH beads for 2 h at 48C. The beads were washed in TNN buer and boiled in SDS sample buer and loaded on a 10% PAGE. After electro transfer onto PVDF membrane, it was probed with antibodies speci®c to Elk-1 as described previously (Wang et al., 1997) .
